News Focus
News Focus
Followers 8
Posts 2018
Boards Moderated 0
Alias Born 07/19/2006

Re: jerrydylan post# 3579

Saturday, 02/03/2007 11:13:19 AM

Saturday, February 03, 2007 11:13:19 AM

Post# of 57919
Good posts all. I guess the best answer is to await the facts on the ground to ripen. There are a hundred or more possible variations on each different outcome: FDA, deals, drugs inlicensed ect . . . the best way to sort through this is the feel your way through each outcome, analyze it, instead of simply selling at a strike price of 3,4,5,10 or whatever. Of course, a strike price brings discipline.

BTW, I've discussed the time length with one of the developers of the TURNS plan last year: his take was about 15 months of a trial duration. So, if Cortex proceeds with a phase IIb ADHD trial for 7-8 weeks(a good hunch)mid year and the more robust TURNS trial takes 15 months in total: 2008 will bring results in ADHD and schizophrenia at the phase IIb level. That ain't bad for a company with a market cap of 37 million, and an enterprise value of 20 million! I now do believe Cortex will get dosing liberalization to allow ADHD. What Stoll has announced their finding gives strong hope for this outcome.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today